These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 18693330)

  • 21. Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
    Danchin N
    Lancet; 2009 Jul; 374(9683):24-5; author reply 26-7. PubMed ID: 19577685
    [No Abstract]   [Full Text] [Related]  

  • 22. Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
    Feeman WE
    Lancet; 2009 Jul; 374(9683):24; author reply 26-7. PubMed ID: 19577687
    [No Abstract]   [Full Text] [Related]  

  • 23. Rosuvastatin in patients with elevated C-reactive protein.
    Jenny-Avital ER
    N Engl J Med; 2009 Mar; 360(10):1039; author reply 1041-2. PubMed ID: 19271275
    [No Abstract]   [Full Text] [Related]  

  • 24. Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
    Bloom JM
    Lancet; 2009 Jul; 374(9683):25-6; author reply 26-7. PubMed ID: 19577688
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
    McKenney JM; Jones PH; Adamczyk MA; Cain VA; Bryzinski BS; Blasetto JW;
    Curr Med Res Opin; 2003; 19(8):689-98. PubMed ID: 14687438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of aggressive lipid controlling therapy for preventing saphenous vein graft disease.
    Hata M; Takayama T; Sezai A; Yoshitake I; Hirayama A; Minami K
    Ann Thorac Surg; 2009 Nov; 88(5):1440-4. PubMed ID: 19853088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
    Segura J; Ruilope LM
    Lancet; 2009 Jul; 374(9683):26; author reply 26-7. PubMed ID: 19577691
    [No Abstract]   [Full Text] [Related]  

  • 29. JUPITER, rosuvastatin, and the European Medicines Agency.
    Ridker PM; Glynn RJ
    Lancet; 2010 Jun; 375(9731):2071. PubMed ID: 20494436
    [No Abstract]   [Full Text] [Related]  

  • 30. Studies examine inflammatory biomarker in prevention and prediction of heart disease.
    Mitka M
    JAMA; 2009 Jan; 301(1):23-4. PubMed ID: 19126804
    [No Abstract]   [Full Text] [Related]  

  • 31. Summaries for patients. Rosuvastatin to prevent heart problems and stroke in persons 70 years or older.
    Ann Intern Med; 2010 Apr; 152(8):I34. PubMed ID: 20404365
    [No Abstract]   [Full Text] [Related]  

  • 32. Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial.
    de Tena JG
    Lancet; 2009 Jul; 374(9683):24; author reply 26-7. PubMed ID: 19577686
    [No Abstract]   [Full Text] [Related]  

  • 33. Cholesterol medication makes a debut in the U.S.
    Heart Advis; 2003 Oct; 6(10):2. PubMed ID: 15106543
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
    Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M
    Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
    Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
    Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rosuvastatin in patients with elevated C-reactive protein.
    Chan PS; Nallamothu BK; Hayward RA
    N Engl J Med; 2009 Mar; 360(10):1039; author reply 1041-2. PubMed ID: 19271273
    [No Abstract]   [Full Text] [Related]  

  • 37. New developments in pharmacotherapy.
    Thompson GR
    Cardiovasc J S Afr; 2004; 15(2):56-8. PubMed ID: 15148538
    [No Abstract]   [Full Text] [Related]  

  • 38. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
    Carter NJ
    Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting HDL-cholesterol to reduce residual cardiovascular risk.
    Iacob AO; Choudhury RP
    Curr Opin Lipidol; 2012 Apr; 23(2):172-4. PubMed ID: 22418577
    [No Abstract]   [Full Text] [Related]  

  • 40. Is it time for HDL to change its tune?
    Nicholls SJ; Puri R
    Circulation; 2013 Sep; 128(11):1175-6. PubMed ID: 24002796
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.